New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 25, 2013
06:33 EDTIMGNImmunoGen says T-DM1 marketing application under review in U.S, Europe
ImmunoGen expects to reports clinical findings for three compounds and expects to advance its fourth compound, IMGN289, into clinical testing.
News For IMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
14:12 EDTIMGNImmunoGen ASCO presentation could be 'turning point,' BBJ says
ImmunoGen CEO Dan Junius says the company's experimental ovarian cancer drug IMGN853, on which data will be presented this Saturday at the American Society of Clinical Oncology, or ASCO, meeting, is the company’s best shot at having a wholly-owned medicine on the market in coming years, according to Boston Business Journal. Reference Link
May 21, 2015
08:39 EDTIMGNNovartis initiates Phase 1 PCA062, triggering milestone payment to ImmunoGen
In a regulatory filing, ImmunoGen disclosed Novartis (NVS) Institutes for BioMedical Research notified ImmunoGen (IMGN) that Novartis had initiated Phase I, first-in-human clinical testing of a product candidate, PCA062, utilizing antibody-drug conjugate technology. Pursuant to the license taken under our 2010 Multi-Target Agreement, this start of clinical testing triggers a $5M milestone payment to ImmunoGen.
May 14, 2015
07:40 EDTIMGNImmunoGen data 'impressive,' says Oppenheimer
Subscribe for More Information
May 13, 2015
17:41 EDTIMGNImmunoGen to present mirvetuximab data at 2015 ASCO meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use